Pfizer reported positive mid-stage trial results for berobenatide, a potential first GLP-1 obesity therapy with monthly dosing, planning up to 10 Phase 3 trials this year. McDonald's is piloting ArchIQ, an AI-powered drive-thru system, automating 90% of orders in five U.S. locations but facing mixed public reactions. Meanwhile, Marvell Technology and Flex will join the S&P 500 index on June 22, replacing Pool Corporation and Campbell's Company, with shares rising on the announcement.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
